4 We have both a late-stage clinical portfolio and an emerging pipeline that span multiple retina mechanisms of action, indications and drug types ABC: antibody biopolymer conjugate; MESI: macular edema secondary to inflammation; AMD: age-related macular degeneration; DR: diabetic retinopathy; RVO: retinal vein occlusion Retinal Vascular Diseases Glaucoma Geographic Atrophy Ocular Inflammation Macular Edema Secondary to Inflammation (MESI) ~800K 1 ~150K* Phase 3 Anti-IL-6, VEGF Trap ABC ® KSI-501 Pre-clinical ABCD ® Duet: NLRP3i + IOP Lowering Glaucoma “Duet” Zenkuda Phase 3 Anti-VEGF ABC ® GA “Duet” Pre-IND Bispecific Antibodies: KSI-102: anti-IL-6, anti-TNF α KSI-103: anti-IL-6, anti-IL-1 KSI-102 & KSI-103 Estimated prevalence across leading causes of vision loss (U.S.) (wAMD, DR, DME, RVO) 1. Nila Kirupaharan et al. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6510. 2. Wong WL, et al. Lancet Glob Health 2014;2:e106–116. 3. Ehrlich JR et al. JAMA Ophthalmol. 2024;142(11):1046–1053. 4. Market Scope. 2024 Retinal Pharmaceuticals Market Report. 5. Roche epidemiology data 2025. 6. Kalva, P et al. Baylor University Medical Center Proceedings , 36 (3), 335–340 *KSI-101 initial addressable population in MESI. Kodiak Data on File and shared Investor R&D Day July 2025. KSI-101 Phase 3 Anti-IL-6, VEGF Trap Bispecific Antibody ABCD ® Duet: NLRP3i + Complement Pre-IND Bispecific Antibodies: Anti-IL-6/Complement; Anti-VEGF/Complement